← 返回

表面工程纳米颗粒在癌症免疫应答和免疫治疗中的应用:现状与未来展望

英文原题:Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects.

查看英文原题

Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects.

PubMed 2022/11/15(内容时间) Biomed Pharmacother

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症免疫治疗是一种通过干预免疫反应过程来抑制肿瘤生长和转移的治疗策略。应用于癌症免疫治疗的策略主要包括阻断免疫检查点、过继转移工程化免疫细胞、细胞因子治疗、癌症疫苗和溶瘤病毒感染。然而,许多因素,如脱靶副作用、免疫抑制细胞浸润和/或免疫检查点表达上调、癌细胞异质性以及抗原呈递缺乏,影响了免疫治疗对癌症的疗效。为了提高靶向免疫治疗的疗效并减少脱靶效应,在过去二十年中,纳米颗粒递送平台越来越多地应用于肿瘤免疫治疗。然而,纳米颗粒仍然受到生物屏障和生物分布挑战的影响,这限制了其整体临床潜力。这促使了一系列工程化纳米颗粒来克服特定障碍,并将载荷的积累转移至肿瘤浸润免疫细胞。近年来,新技术和化学方法被用于修饰或功能化纳米颗粒表面。本综述讨论了表面工程化纳米颗粒在诱导肿瘤免疫反应和免疫治疗方面的最新进展,以及下一代纳米药物开发的未来方向。

展开英文摘要原文

Cancer immunotherapy is a therapeutic strategy to inhibit tumor growth and metastasis by intervening in the immune response process. Strategies applied to cancer immunotherapy mainly include blocking immune checkpoints, adoptive transfer of engineered immune cells, cytokine therapy, cancer vaccines, and oncolytic virus infection.

However, many factors, such as off-target side effects, immunosuppressive cell infiltration and/or upregulation of immune checkpoint expression, cancer cell heterogeneity, and lack of antigen presentation, affect the therapeutic effect of immunotherapy on cancer. To improve the efficacy of targeted immunotherapy and reduce off-target effects, over the past two decades, nanoparticle delivery platforms have been increasingly used in tumor immunotherapy.

However, nanoparticles are still subject to biological barriers and biodistribution challenges, which limit their overall clinical potential. This has prompted a series of engineered nanoparticles to overcome specific obstacles and transfer the accumulation of payloads to tumor-infiltrating immune cells.

In recent years, new techniques and chemical methods have been employed to modify or functionalize the surfaces of nanoparticles. This review discusses the recent progress of surface-engineered nanoparticles in inducing tumor immune responses and immunotherapy, as well as future directions for the development of next-generation nanomedicines.

论文信息

作者
Chen J、Cong X
第一作者单位
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110000, Liaoning Province, China.China
通讯作者单位
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110000, Liaoning Province, China. Electronic address: cara_cong@163.com.China
文献类型
综述
期刊
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2023 Jan
原文标识
PubMed 36399829 · DOI 10.1016/j.biopha.2022.113998